Videos

In this Exclusive Interview transcript John Buse talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Observe 4D real-world study on SGLT2 Inhibitors.

In this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Observe 4D real-world study.

In part 1 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about his excitement over the information presented at the ADA conference about the GLP-1 and SGLT-2 drugs, and how to implement their use.

In part 2 of this Exclusive Interview, John Buse explains the Observe 4D real-world study, which looked at the relationship between the use of SGLT-2 and heart failure and amputation outcomes, in a conversation with Diabetes in Control Publisher Steve Freed.

In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.

In part 4 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about insurance coverage of SGLT-2 drugs and the challenges for patients with heart and kidney issues.

In part 5 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about studies on the use of SGLT in other populations — people without diabetes, people with kidney disease, etc.

In part 6 of this Exclusive Interview, John Buse compares the Observe 4D study to other similar studies in a conversation with Diabetes in Control Publisher Steve Freed.

In part 7 of this Exclusive Interview, John Buse urges other medical professionals to weigh the risks and benefits of using SGLT in a conversation with Diabetes in Control Publisher Steve Freed.

In part 8, the conclusion of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the good and bad effects of using SGLT2 for patients who have type 1.